Now showing items 41-60 of 3158

    • MUTYH-Associated Polyposis: The Irish Experience>. 

      McVeigh, TP; Duff, M; Carroll, C; O'Shea, R; Bradley, L; Farrell, M; Gallagher, DJ; Clabby, C; Green, AJ (2016-12-12)
      MUTYH is involved in DNA damage repair. Bi-allelic MUTYH mutations predispose to polyposis and gastrointestinal malignancies, distinct genetically from autosomal dominant familial adenomatous polyposis coli. Two common ...
    • Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. 

      Sestak, I; Martín, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodríguez-Lescure, A; Gnant, M (2019-07)
      PURPOSE: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we ...
    • Pazopanib in advanced soft tissue sarcomas. 

      Lee, ATJ; Jones, RL; Huang, PH (2019)
      Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ...
    • Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. 

      Zheng, G; Chattopadhyay, S; Sud, A; Sundquist, K; Sundquist, J; Försti, A; Houlston, R; Hemminki, A; Hemminki, K (2019-04)
      Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks ...
    • Resolving genetic heterogeneity in cancer. 

      Turajlic, S; Sottoriva, A; Graham, T; Swanton, C (2019-07)
      To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the genetic landscape of most cancer types, and ...
    • Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. 

      Moss, CA; Cojocaru, E; Hanwell, J; Ward, S; Xu, W; van Zyl, M; O'Leary, L; de Bono, JS; Banerji, U; Kaye, SB; Minchom, A; George, AJ; Lopez, J; McVeigh, TP (2019-06)
      BACKGROUND: Molecular aberrations in cancer may represent therapeutic targets, and, if arising from the germline, may impact further cancer risk management in patients and their blood relatives. Annually, 600-700 patients ...
    • Targeting the PI3-kinase pathway in triple negative breast cancer. 

      Pascual, J; Turner, NC (2019-05-03)
      Triple negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation of signalling through the PI3 kinase and AKT signalling pathway is one of the most frequent ...
    • NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL 

      Larrayoz, M; Rose-Zerilli, MJ; Parker, H; Blakemore, SJ; Forster, J; Davis, Z; Steele, AJ; Else, M; Catovsky, D; Oscier, DG; Strefford, JC (2016-06)
    • Reply to 'Revisiting signatures of neutral tumor evolution in the light of complexity of cancer genomic data'. 

      Williams, MJ; Werner, B; Heide, T; Barnes, CP; Graham, TA; Sottoriva, A (2018-12)
    • A novel amplitude binning strategy to handle irregular breathing during 4DMRI acquisition: improved imaging for radiotherapy purposes. 

      van Kesteren, Z; van der Horst, A; Gurney-Champion, OJ; Bones, I; Tekelenburg, D; Alderliesten, T; van Tienhoven, G; Klaassen, R; van Laarhoven, HWM; Bel, A (2019-05-14)
      BACKGROUND: For radiotherapy of abdominal cancer, four-dimensional magnetic resonance imaging (4DMRI) is desirable for tumor definition and the assessment of tumor and organ motion. However, irregular breathing gives rise ...
    • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

      Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
      Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
    • Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis. 

      Ahmed, K; McVeigh, T; Cerneviciute, R; Mohamed, S; Tubassam, M; Karim, M; Walsh, S (2018-11-13)
      BACKGROUND: Different methods to prevent contrast-associated acute kidney injury (CA-AKI) have been proposed in recent years. We performed a mixed treatment comparison to evaluate and rank suggested interventions. METHODS: ...
    • Reply to 'Neutral tumor evolution?' 

      Heide, T; Zapata, L; Williams, MJ; Werner, B; Caravagna, G; Barnes, CP; Graham, TA; Sottoriva, A (2018-12)
    • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials 

      Boddington, C; Bradley, R; Braybrooke, J; Burrett, J; Clarke, M; Davies, C; Davies, L; Dodwell, D; Duane, F; Evans, V; Gettins, L; Godwin, J; Gray, R; Hills, R; James, S; Liu, H; Liu, Z; MacKinnon, E; Mannu, G; McGale, P; McHugh, T; Morris, P; Pan, H; Peto, R; Read, S; Taylor, C; Wang, Y; Wang, Z; Bradley, R; Braybrooke, J; Gray, R; Bergh, J; Peto, R; Gray, R; Bradley, R; Braybrooke, J; Liu, Z; Peto, R; Davies, L; Dodwell, D; McGale, P; Pan, H; Taylor, C; Barlow, W; Bliss, J; Bruzzi, P; Cameron, D; Fountzilas, G; Loibl, S; Mackey, J; Martin, M; Del Mastro, L; Moebus, V; Nekljudova, V; De Placido, S; Swain, S; Untch, M; Pritchard, KI; Bergh, J; Norton, L; Fasching, P; Harbeck, N; Untch, M; Piedbois, P; Gnant, M; Steger, G; Di Leo, A; Dolci, S; Francis, P; Larsimont, D; Nogaret, JM; Philippson, C; Piccart-Gebhart, MJ; Linn, S; Peer, P; Tjan-Heijnen, V; Vliek, S; Mackey, J; Martin, M; Slamon, D; Bartlett, JMS; Bramwell, VH; Chen, BE; Chia, SKL; Gelmon, K; Goss, PE; Levine, MN; Parulekar, W; Pater, JL; Pritchard, KI; Rakovitch, E; Shepherd, LE; Tu, D; Whelan, T; Berry, D; Broadwater, G; Cirrincione, C; Muss, H; Norton, L; Weiss, RB; Shan, Y; Shao, YF; Wang, X; Xu, B; Zhao, DB; Bartelink, H; Bijker, N; Bogaerts, J; Cardoso, F; Cufer, T; Julien, JP; Poortmans, PM; Rutgers, E; van de Velde, CJH; Carrasco, E; Martin, M; Segui, MA; Blohmer, JU; Costa, SD; Gerber, B; Jackisch, C; Loibl, S; Nekljudova, V; von Minckwitz, G; Bruzzi, P; Giuliano, M; De laurentiis, M; De Placido, S; Del Mastro, L; Bamia, C; Fountzilas, G; Koliou, G-A; Mavroudis, D; A'Hern, R; Bliss, J; Cameron, D; Ellis, P; Kilburn, L; Morden, J; Yarnold, JR; Sadoon, M; Tulusan, AH; Anderson, S; Bass, G; Costantino, J; Dignam, J; Fisher, B; Geyer, C; Mamounas, EP; Paik, S; Redmond, C; Swain, S; Wickerham, L; Wolmark, N; Del Mastro, L; Venturini, M; Bighin, C; Bruzzi, P; Del Mastro, L; Pastorino, S; Pronzato, P; Sertoli, MR; Barlow, W; Bergh, J; Foukakis, T; Pritchard, KI; Swain, S; Cameron, D; Albain, K; Anderson, S; Arriagada, R; Barlow, W; Bartlett, J; Bergsten-Nordstrom, E; Bliss, J; Boccardo, F; Bradley, R; Brain, E; Braybrooke, J; Carey, L; Clarke, M; Coates, A; Coleman, R; Correa, C; Costantino, J; Cuzick, J; Davidson, N; Davies, C; Davies, L; Di Leo, A; Dodwell, D; Dowsett, M; Duane, F; Ewertz, M; Forbes, J; Francis, P; Gelber, R; Gnant, M; Goldhirsch, A; Goodwin, P; Gray, R; Hayes, D; Hill, C; Ingle, J; Jagsi, R; Janni, W; Liu, Z; Loibl, S; MacKinnon, E; Mannu, G; Martin, M; McGale, P; Mukai, H; Nekljudova, V; Norton, L; Ohashi, Y; Paik, S; Pan, H; Peto, R; Piccart, M; Pierce, L; Poortmans, P; Raina, V; Ravdin, P; Rea, D; Regan, M; Robertson, J; Rutgers, E; Slamon, D; Sparano, J; Steger, G; Taylor, C; Tutt, A; Viale, G; Wang, X; Whelan, T; Wilcken, N; Wolmark, N; Wood, W; Zambetti, M; EBCTCG (2019-04-06)
    • MR guided high intensity focused ultrasound (MRgHIFU) for treating recurrent gynaecological tumours: a pilot feasibility study. 

      Giles, SL; Imseeh, G; Rivens, I; Ter Haar, GR; Taylor, A; deSouza, NM (2019-06)
      OBJECTIVE: To assess the feasibility of targeting recurrent gynaecological tumours with MR guided high intensity focused ultrasound (MRgHIFU). METHODS: 20 patients with recurrent gynaecological tumours were prospectively ...
    • Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. 

      Siskos, AP; Jain, P; Römisch-Margl, W; Bennett, M; Achaintre, D; Asad, Y; Marney, L; Richardson, L; Koulman, A; Griffin, JL; Raynaud, F; Scalbert, A; Adamski, J; Prehn, C; Keun, HC (2017-01-03)
      A critical question facing the field of metabolomics is whether data obtained from different centers can be effectively compared and combined. An important aspect of this is the interlaboratory precision (reproducibility) ...
    • ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. 

      Carvalho, D; Taylor, KR; Olaciregui, NG; Molinari, V; Clarke, M; Mackay, A; Ruddle, R; Henley, A; Valenti, M; Hayes, A; Brandon, ADH; Eccles, SA; Raynaud, F; Boudhar, A; Monje, M; Popov, S; Moore, AS; Mora, J; Cruz, O; Vinci, M; Brennan, PE; Bullock, AN; Carcaboso, AM; Jones, C (2019)
      Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1, encoding the serine/threonine kinase ALK2. Despite being an amenable drug ...
    • Effect of acute total sleep deprivation on plasma melatonin, cortisol and metabolite rhythms in females. 

      Honma, A; Revell, VL; Gunn, PJ; Davies, SK; Middleton, B; Raynaud, FI; Skene, DJ (2019-03-30)
      Disruption to sleep and circadian rhythms can impact on metabolism. The study aimed to investigate the effect of acute sleep deprivation on plasma melatonin, cortisol and metabolites, to increase understanding of the ...
    • SIRT3 controls brown fat thermogenesis by deacetylation regulation of pathways upstream of UCP1. 

      Sebaa, R; Johnson, J; Pileggi, C; Norgren, M; Xuan, J; Sai, Y; Tong, Q; Krystkowiak, I; Bondy-Chorney, E; Davey, NE; Krogan, N; Downey, M; Harper, M-E (2019-07)
      OBJECTIVE: Brown adipose tissue (BAT) is important for thermoregulation in many mammals. Uncoupling protein 1 (UCP1) is the critical regulator of thermogenesis in BAT. Here we aimed to investigate the deacetylation control ...